Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $122

Benzinga Newsdesk www.benzinga.com Positive 91.6%

Neg 0% Neu 0% Pos 91.6%

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $105 to $122.